Recapping ASH 2024 Highlights, with Steven Fein, MD

Hematology represents an area of immense progress and innovation in recent years, with no greater example of this continued advancement than the American Society of Hematology (ASH) annual meeting.

In this video series, Steven Fein, MD, a telehealth hematologist with HemeOnCall, breaks down the most impactful news and updates from ASH 2024 and the remainder of the past year, with a focus on iron deficiency anemia, sickle cell disease, and other nononcology hematologic conditions.

In this, the first in our 5-part series, Fein highlights key findings from ASH 2024. He begins by discussing the promising results for rilzabrutinib, a BTK inhibitor shown to be safe and effective for patients with immune thrombocytopenia (ITP), including those refractory to multiple treatments.

Fein also reviews a clinical trial confirming the safety and efficacy of hydroxyurea in patients with hemoglobin SC disease, solidifying its role in treatment strategies. Additionally, he discusses new studies on iron infusions, emphasizing evidence supporting total dose iron infusion as a cost-effective and efficient approach, particularly for women requiring iron replacement.

Relevant disclosures for Fein include Pharmacosmos Therapeutics, Sobi, Amgen, Agios, BeiGene, and others.